Feasibility study of dose eslation and concentration in stereotactic body radiotherapy (SBRT) for lung tumors

Feasibility study of dose eslation and concentration in stereotactic body radiotherapy (SBRT) for lung tumors - Feasibility study of dose eslation and concentration in SBRT for lung tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006172

Enrollment

Registered

2011-08-16

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T1-4N0M0 non-small cell lung cancer solitary or ipsilateral two lung metastasis

Interventions

Stereotactic body radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1-1.Histologically or cytologically (class IV or V) diagnosed NSCLC or solitary or ipsilateral two lung metastasis 1-2.radiographically diagnosed NSCLC (with no elevation of NSE or proGRP) or solitary or ipsilateral two lung metastasis 2.CT diagnosis within 60 days and FDG-PET diagnosis within 90 days 3.No other intrathoracic lesions 4.Dose constraints of the organs at risk seem to be limited within range 5.No previous thoracic radiation 6.No previous chemotherapy 7.ECOG PS=0-2 8.GOLD stage 0-II 9.Written informed consent

Exclusion criteria

Exclusion criteria: 1. apparent interstitial pneumonitis and fibrosis 2. active inflamation without oral drugs 3. double cancer 4. pregnancy 5. psychiatric disorder 6. steroid administration 7. oxygen administration 8. fever of 38.0 degrees centigrade or higher 9. narcotics administration for coughing

Design outcomes

Primary

Measure	Time frame
incidence of Grade 2 or more radiation pneumonits within 180 days after stereotactic radiotherapy	—

Secondary

Measure	Time frame
incidence of Grade 3 or more radiation pneumonitis, adverse events, severe adverse events, local progression free survival, 3-year local progression free survival, event free survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026